文献速递妇科肿瘤

一线仑伐替尼联合帕博利珠单抗对比化疗治疗晚期子宫内膜癌:一项随机、开放标签、III期试验

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
PubMed 文献 · J Clin Oncol · 2024-11-26

LEAP-001研究纳入842例III-IV期或复发性子宫内膜癌患者,一线随机接受仑伐替尼+帕博利珠单抗或紫杉醇+卡铂。在错配修复功能完整(pMMR)人群中,中位无进展生存期(PFS)9.6 vs 10.2个月(HR 0.99),中位总生存期(OS)30.9 vs 29.4个月(HR 1.02),未达到预设的PFS或OS统计学标准。

要点

  • pMMR人群一线len+pembro对比化疗:中位PFS 9.6 vs 10.2个月(HR 0.99),中位OS 30.9 vs 29.4个月(HR 1.02)。
  • 全人群描述性分析:中位PFS 12.5 vs 10.2个月(HR 0.91),中位OS 37.7 vs 32.1个月(HR 0.93)。
  • ≥3级治疗相关不良事件:len+pembro组331/420(79%),化疗组274/411(67%)。

核心结论

  • 一线仑伐替尼联合帕博利珠单抗对比化疗在pMMR晚期子宫内膜癌中未达到预设的PFS或OS统计学标准。

研究设计与样本

  • III期、随机、开放标签、欧洲妇科肿瘤试验网络-en9/LEAP-001研究(NCT03884101)。
  • 纳入III至IV期或复发性、影像学可见的子宫内膜癌患者,且既往未接受化疗或在新辅助/辅助铂类化疗后≥6个月无疾病进展。
  • 按1:1随机分配至仑伐替尼20 mg每日一次+帕博利珠单抗200 mg每3周一次,或紫杉醇175 mg/m2+卡铂AUC 6 mg/mL/min每3周一次。
  • 主要终点为PFS和OS,在pMMR人群和全人群中评估。
  • 共842例患者随机分配(len+pembro组n=420,其中pMMR n=320;化疗组n=422,其中pMMR n=322)。

主要发现

  • 最终分析(数据截止2023年10月2日)时,pMMR人群中位PFS(95%CI)为9.6(8.2至11.9)个月 vs 10.2(8.4至10.5)个月(HR 0.99,95%CI 0.82至1.21)。
  • 全人群中位PFS(95%CI)为12.5(10.3至15.1)个月 vs 10.2(8.4至10.4)个月(HR 0.91,95%CI 0.76至1.09;描述性分析)。
  • pMMR人群中位OS(95%CI)为30.9(25.4至37.7)个月 vs 29.4(26.2至35.4)个月(HR 1.02,95%CI 0.83至1.26;非劣效性P=0.246,按多重性控制策略未达统计学显著)。
  • 全人群中位OS(95%CI)为37.7(32.2至43.6)个月 vs 32.1(27.2至35.7)个月(HR 0.93,95%CI 0.77至1.12)。
  • ≥3级治疗相关不良事件在len+pembro组为331/420(79%),化疗组为274/411(67%)。

关键数值与推荐

  • OS非劣效性检验:最终分析时多重调整的单侧名义α=0.0159,零假设检验HR=1.1。
  • pMMR人群OS非劣效性P=0.246,未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase III Study 309/KEYNOTE-775. We report results from the phase III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101) that evaluated len + pembro versus chemotherapy in first-line aEC. METHODS: Patients with stage III to IV or recurrent, radiographically apparent EC and no previous chemotherapy or disease progression ≥6 months after neo/adjuvant platinum-based chemotherapy were randomly assigned 1:1 to lenvatinib 20 mg once daily plus pembrolizumab 200 mg once every 3 weeks or paclitaxel 175 mg/m2 plus carboplatin AUC 6 mg/mL/min once every 3 weeks. Primary end points were PFS and OS, evaluated in the mismatch repair-proficient (pMMR) and all-comers populations. Noninferiority was assessed for OS at final analysis (FA) for len + pembro versus chemotherapy (multiplicity-adjusted, one-sided nominal alpha, .0159; null hypothesis-tested hazard ratio [HR], 1.1). RESULTS: Eight hundred forty-two patients were randomly assigned (len + pembro, n = 420 [pMMR population, n = 320]; chemotherapy, n = 422 [pMMR population, n = 322]). At FA (data cutoff, October 2, 2023), median PFS (95% CI) in the pMMR population was 9.6 (8.2 to 11.9) versus 10.2 (8.4 to 10.5) months with len + pembro versus chemotherapy (hazard ratio [HR], 0.99 [95% CI, 0.82 to 1.21]) and among all-comers was 12.5 (10.3 to 15.1) versus 10.2 (8.4 to 10.4) months (HR, 0.91 [95% CI, 0.76 to 1.09]; descriptive analyses). Median OS (95% CI) in the pMMR population was 30.9 (25.4 to 37.7) versus 29.4 (26.2 to 35.4) months with len + pembro versus chemotherapy (HR, 1.02 [95% CI, 0.83 to 1.26]; noninferiority P = .246, not statistically significant per multiplicity control strategy) and among all-comers was 37.7 (32.2 to 43.6) versus 32.1 (27.2 to 35.7) months (HR, 0.93 [95% CI, 0.77 to 1.12]). Grade ≥3 treatment-related adverse events occurred in 331/420 (79%) versus 274/411 (67%) treated patients. CONCLUSION: First-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Marth C, Moore RG, Bidziński M, et al. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2024. PMID: 39591551. doi:10.1200/JCO-24-01326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。